IFNA2 and neoplasm: These apparently conflicting results can be explained by recent findings, which illustrate that IFN-α-deficient tumor-associated DCs accumulate in aggressive tumors and lead to the expansion of regulatory T cells (Treg), which contribute to tumor immune tolerance and a poor clinical outcome (31).